<DOC>
	<DOCNO>NCT02338128</DOCNO>
	<brief_summary>The purpose study determine whether Febuxostat could protect cardiovascular function peritoneal dialysis patient lower serum uric acid .</brief_summary>
	<brief_title>The Cardiovascular Protective Effects Febuxostat Peritoneal Dialysis Patients</brief_title>
	<detailed_description>Patients 3-month-history peritoneal dialysis hyperuricemia . Use Febuxostat control serum uric acid 1 year . To observe cardiovascular event patient , compare evaluate change heart function , heart construction , serum cardiac marker brain natriuretic peptide ( BNP ) level Febuxostat treatment .</detailed_description>
	<mesh_term>Hyperuricemia</mesh_term>
	<mesh_term>Febuxostat</mesh_term>
	<criteria>Peritoneal dialysis 3 month hyperuricemia . 1 . Acute hepatopathy liver dysfunction ( Aspartate transaminase and/or alanine aminotransferase exceed 2 time normal range ) 2 . Heart failure ( stage IV , NYHA ) , unstable angina , acute stroke 3 . Severe lung disease cancer 4. unable sign inform consent form disagree followingup .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>peritoneal dialysis</keyword>
	<keyword>hyperuricemia</keyword>
	<keyword>cardiovascular</keyword>
	<keyword>Febuxostat</keyword>
</DOC>